Can-Fites Stage II clinical research of CF101 provides excellent results Can-Fite BioPharma.

Furthermore & most importantly success in these scholarly research validates the technology system of the company.. Can-Fite’s Stage II clinical research of CF101 provides excellent results Can-Fite BioPharma , a biotechnology company traded in the Tel Aviv STOCK MARKET, an Israeli Biopharmaceutical firm, announced today that its 75-patient Phase II clinical research with CF101 to treat patients with moderate to serious Psoriasis has successfully met its main objectives. Patients in this double-blind study were randomly assigned to at least one 1, 2 or 4 mg of CF101 or placebo twice daily. The drug was used orally as a monotherapy for 12 weeks. By many analyses, the individual group getting 2 mg CF101> Related StoriesTWi Biotechnology gets notice of patent allowance covering use of AC-201 medication in diabetes treatmentNational Psoriasis Base introduces patient-centered research networkPhase II psoriasis study shows efficacy of Boehringer Ingelheim's BI 655066 over ustekinumabDr.She was 80. In addition to her film work, Francis played a mannequin who comes to life in an episode of it series ‘The Twilight Zone’ and had the name role in the 1960s series ‘Honey West,’ in which she played an exclusive detective with a pet ocelot. Pancreatic cancer is certainly a notorious killer. Each full calendar year in the U.S., a lot more than 43,000 are diagnosed with the condition – and only 5.6 % of people are still alive five years after being diagnosed. Risk elements for the condition include smoking cigarettes, diabetes, and certain hereditary conditions.